Imperial College London
Portrait Picture

ProfessorAnnaRandi

Faculty of Medicine, National Heart & Lung Institute

Head of Section for Vascular Science
 
 
 
//

Contact

 

a.randi Website

 
 
//

Location

 

L-block, room 533Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Randi:2017:10.1111/jth.13551,
author = {Randi, AM and Laffan, MA},
doi = {10.1111/jth.13551},
journal = {Journal of Thrombosis and Haemostasis},
pages = {13--20},
title = {Von Willebrand factor and angiogenesis: basic and applied issues},
url = {http://dx.doi.org/10.1111/jth.13551},
volume = {15},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The recent discovery that von Willebrand factor (VWF) regulates blood vessel formation has opened a novel perspective on the function of this complex protein. VWF was discovered as a key component of haemostasis, capturing platelets at sites of endothelial damage and synthesized in megakaryocytes and endothelial cells (EC). In recent years, novel functions and binding partners have been identified for VWF. The finding that loss of VWF in EC results in enhanced, possibly dysfunctional angiogenesis is consistent with the clinical observations that in some patients with Von Willebrand disease (VWD), vascular malformations can cause severe gastrointestinal (GI) bleeding. In vitro and in vivo studies indicate that VWF can regulate angiogenesis through multiple pathways, both intracellular and extracellular, although their relative importance is still unclear. Investigation of these pathways has been greatly facilitated by the ability to isolate EC from progenitors circulating in the peripheral blood of normal controls and patients with VWD. In the next few years, these will yield further evidence on the molecular pathways controlled by VWF and shed light on this novel and fascinating area of vascular biology. In this article, we will review the evidence supporting a role for VWF in blood vessel formation, the link between VWF dysfunction and vascular malformations causing GI bleeding and how they may be causally related. Finally, we will discuss how these findings point to novel therapeutic approaches to bleeding refractory to VWF replacement therapy in VWD.
AU  - Randi,AM
AU  - Laffan,MA
DO  - 10.1111/jth.13551
EP  - 20
PY  - 2017///
SN  - 1538-7933
SP  - 13
TI  - Von Willebrand factor and angiogenesis: basic and applied issues
T2  - Journal of Thrombosis and Haemostasis
UR  - http://dx.doi.org/10.1111/jth.13551
UR  - http://www.ncbi.nlm.nih.gov/pubmed/27778439
UR  - http://hdl.handle.net/10044/1/42796
VL  - 15
ER  -
Download